^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up

    Published date:
    07/28/2019
    Excerpt:
    For three ALK-rearranged patients, ipilimumab PFS was 24.1 months.
    Trial ID:
    NCT01998126